Combination of an inhibitor of PARP with an inhibitor of GSK-3 or DOT1L
US10799501B2 · kind B2 · utility
Assignee
Inventor
Key dates
| Filing date | Nov 4, 2016 |
| Grant date | Oct 13, 2020 |
| Priority date | — |
| Expiry date | Nov 4, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/02
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Provided herein is a pharmaceutical combination comprising (a) a poly-(ADP-ribose)-polymerase (PARP) inhibitor and (b) a second agent comprising (i) an inhibitor of glycogen synthase kinase 3 (GSK-3) or (ii) an inhibitor of disrupter of telomeric silencing 1-like (DOT1L). Also provided is a method of treating a subject suffering from acute myeloid leukaemia, comprising administering to the subject a therapeutically effective amount of the pharmaceutical combination. There is also described herein a method for selecting a therapy for a subject suffering from acute myeloid leukaemia, comprising determining whether a chromosomal abnormality at 11q23 is present in a sample obtained from the subject; wherein if the chromosomal abnormality at 11q23 is present in the sample, a therapy comprising combined administration of (a) a poly-(ADP-ribose)-polymerase (PARP) inhibitor and (b) a second agent comprising (i) an inhibitor of glycogen synthase kinase 3 (GSK-3) or (ii) an inhibitor of disrupter of telomeric silencing 1-like (DOT1L) is selected for the subject.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.